{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:07Z","timestamp":1792508587236,"version":"4.5.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>This matching-adjusted indirect comparison evaluated the efficacy of epcoritamab vs standard of care (SOC), mosunetuzumab, or odronextamab, and assessed safety vs mosunetuzumab and odronextamab. Individual patient-level data from the EPCORE NHL-1 follicular lymphoma (FL) cohort for epcoritamab were used with pooled data from SCHOLAR-5 for SOC (mostly chemoimmunotherapy [CIT]), and aggregate data from GO29781 for mosunetuzumab and ELM-2 for odronextamab. Trial populations were match-adjusted using propensity score weights for key baseline characteristics. Compared with SOC\/CIT, epcoritamab provided significantly higher response rates (overall response rate [ORR], 90.9% vs 56.8%; P &amp;lt; .001; complete response [CR] rate, 73.7% vs 32.0%; P &amp;lt; .001). Epcoritamab showed numerically higher ORR (90.9% vs 80.0%; P = .067) and CR rate (72.8% vs 60.0%; P = .159) vs mosunetuzumab. Epcoritamab provided significantly higher ORR (91.5% vs 80.5%; P = .026) and numerically lower CR rate (67.5% vs 73.4%; P = .428) vs odronextamab. Epcoritamab did not have any grade \u22653 cytokine release syndrome (CRS) or immune effector cell\u2013associated neurotoxicity syndrome (ICANS; any grade) events compared with CRS (grade \u22653) in 2.2% and 3.9% and ICANS in 4.4% and 0.8% of patients treated with mosunetuzumab and odronextamab, respectively (P &amp;lt; .001). In addition to being a convenient subcutaneous option, epcoritamab showed significantly superior response rates and survival outcomes vs SOC\/CIT among patients with relapsed or refractory FL after \u22652 systemic therapies. Epcoritamab also exhibited clinically relevant, numerically higher ORRs and demonstrated improved safety for CRS (grade \u22653) and ICANS vs mosunetuzumab or odronextamab. These trials were registered at www.ClinicalTrials.gov as #NCT03625037, #NCT02500407, and #NCT03888105.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015274","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:55:32Z","timestamp":1749138932000},"page":"3754-3765","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma"],"prefix":"10.1182","volume":"9","author":[{"given":"Alexey V.","family":"Danilov","sequence":"first","affiliation":[{"name":"1Department of Hematology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Kambhampati Thiruvengadam","sequence":"additional","affiliation":[{"name":"1Department of Hematology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-1548","authenticated-orcid":false,"given":"Kim","family":"Linton","sequence":"additional","affiliation":[{"name":"2The Christie NHS Foundation Trust, Manchester Cancer Research Center, and Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3999-1505","authenticated-orcid":false,"given":"Karen","family":"Cumings","sequence":"additional","affiliation":[{"name":"3OPEN Health, Hingham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Chirikov","sequence":"additional","affiliation":[{"name":"3OPEN Health, Hingham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[{"name":"4Genmab US Inc, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savreet","family":"Bains Chawla","sequence":"additional","affiliation":[{"name":"4Genmab US Inc, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindit","family":"Chhibber","sequence":"additional","affiliation":[{"name":"4Genmab US Inc, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rivas Navarro","sequence":"additional","affiliation":[{"name":"5Genmab, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Marques Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"4Genmab US Inc, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[{"name":"6AbbVie, Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ding","sequence":"additional","affiliation":[{"name":"4Genmab US Inc, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2737-1365","authenticated-orcid":false,"given":"Abualbishr","family":"Alshreef","sequence":"additional","affiliation":[{"name":"6AbbVie, Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Favaro","sequence":"additional","affiliation":[{"name":"5Genmab, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hoehn","sequence":"additional","affiliation":[{"name":"4Genmab US Inc, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"7Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia L\u2019Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"2","key":"2025081209263710200_bib1","first-page":"97","article-title":"Follicular lymphoma: a focus on current and emerging therapies","volume":"36","author":"Cahill","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"2025081209263710200_bib2","first-page":"5","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"2025081209263710200_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ejh.12335","article-title":"Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025081209263710200_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12885-023-10546-6","article-title":"Clinical outcomes in patients relapsed\/refractory after \u22652 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis","volume":"23","author":"Kanters","year":"2023","journal-title":"BMC Cancer"},{"key":"2025081209263710200_bib5","doi-asserted-by":"crossref","first-page":"1120358","DOI":"10.3389\/fonc.2023.1120358","article-title":"Treatment selection for patients with relapsed or refractory follicular lymphoma","volume":"13","author":"Skarbnik","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"2025081209263710200_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.36469\/jheor.2022.38070","article-title":"Treatment patterns of follicular lymphoma in the United States: a claims analysis","volume":"9","author":"Huntington","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"issue":"7","key":"2025081209263710200_bib7","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s12325-021-01738-2","article-title":"Phase III clinical trials in first-line follicular lymphoma: a review of their design and interpretation","volume":"38","author":"Bachy","year":"2021","journal-title":"Adv Ther"},{"issue":"14","key":"2025081209263710200_bib8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"2025081209263710200_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/aol-20-51","article-title":"Frontline management for follicular lymphoma patients: a narrative review","volume":"5","author":"Luminari","year":"2021","journal-title":"Ann Lymph"},{"issue":"28","key":"2025081209263710200_bib10","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab (R(2)) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025081209263710200_bib11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"2025081209263710200_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","article-title":"Current and future therapies for follicular lymphoma","volume":"13","author":"Zinzani","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2025081209263710200_bib13","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1097\/HS9.0000000000000156","article-title":"New treatment options in advanced stage follicular lymphoma","volume":"2","author":"H\u00fcbel","year":"2018","journal-title":"Hemasphere"},{"key":"2025081209263710200_bib14","doi-asserted-by":"crossref","first-page":"20406207221142133","DOI":"10.1177\/20406207221142133","article-title":"CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"2025081209263710200_bib15","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. 2024. Accessed 12 June 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma."},{"issue":"30","key":"2025081209263710200_bib16","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025081209263710200_bib17","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"5","key":"2025081209263710200_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2025081209263710200_bib19","volume-title":"Epkinly. Package insert","year":"2024"},{"key":"2025081209263710200_bib20","author":"Schuster","year":"9-12  2023;"},{"key":"2025081209263710200_bib21","unstructured":"Conroy\n              R\n            \n          . Epcoritamab earns FDA BTD in relapsed\/refractory follicular lymphoma. Cancer Network; 2023. Accessed 14 November 2024. https:\/\/www.cancernetwork.com\/view\/epcoritamab-earns-fda-btd-in-relapsed-refractory-follicular-lymphoma."},{"issue":"8","key":"2025081209263710200_bib22","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025081209263710200_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2023-173692","article-title":"Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study [abstract]","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081209263710200_bib24","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2023-181650","article-title":"Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) with extended follow-up [abstract]","volume":"142","author":"Villasboas","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025081209263710200_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025081209263710200_bib26","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"2025081209263710200_bib27","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1200\/JCO.2024.42.16_suppl.7015","article-title":"EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: expanding the clinical utility of epcoritamab in relapsed or refractory (R\/R) FL [abstract]","volume":"42","author":"Vose","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025081209263710200_bib28","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2023-179887","article-title":"Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort [abstract]","volume":"142","author":"Linton","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025081209263710200_bib29","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025081209263710200_bib30","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025081209263710200_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-023-01462-0","article-title":"Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting","volume":"16","author":"Cao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025081209263710200_bib32","author":"Kim","year":"10-13  2022;"},{"issue":"7","key":"2025081209263710200_bib33","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1097\/HS9.0000000000000745","article-title":"A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)","volume":"6","author":"Salles","year":"2022","journal-title":"Hemasphere"},{"key":"2025081209263710200_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CMAR.S381493","article-title":"Targeted treatment of relapsed or refractory follicular lymphoma: focus on the therapeutic potential of mosunetuzumab","volume":"15","author":"Lopedote","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"suppl 1","key":"2025081209263710200_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20\u00d7CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy [abstract]","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"issue":"suppl 2","key":"2025081209263710200_bib36","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract]","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081209263710200_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"2025081209263710200_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.HS9.0000967800.55471.36","article-title":"Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in patients with high-risk follicular lymphoma, regardless of POD24 status [abstract]","volume":"7","author":"Sureda","year":"2023","journal-title":"HemaSphere"},{"key":"2025081209263710200_bib39","doi-asserted-by":"crossref","first-page":"102553","DOI":"10.1016\/j.eclinm.2024.102553","article-title":"Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022","volume":"71","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2025081209263710200_bib40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1134\/S1019331622040074","article-title":"The Omicron variant of the Sars-Cov-2 virus as the dominant agent of a new risk of disease amid the COVID-19 pandemic","volume":"92","author":"Onishchenko","year":"2022","journal-title":"Her Russ Acad Sci"},{"issue":"16","key":"2025081209263710200_bib41","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"2025081209263710200_bib42","author":"Vitolo","year":"13-16  2024"},{"issue":"1","key":"2025081209263710200_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel [published correction appears in J Hematol Oncol. 2018;11(1):81]","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2025081209263710200_bib44","author":"Jurczak","year":"13-16  2024;"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3754\/2404016\/blooda_adv-2024-015274-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3754\/2404016\/blooda_adv-2024-015274-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:26:47Z","timestamp":1755005207000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3754\/537623\/Indirect-comparison-of-epcoritamab-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":44,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015274","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,25]]}}}